English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To test the efficacy and safety of osmotic release oral system ( OROS ) methylphenidate ( MPH ) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder ( ADHD ) and prevent any drug relapse in individuals with a co‐diagnosis of  ADHD  and amphetamine dependence.    Design  Randomized placebo‐controlled 24‐week double‐blind trial with parallel groups design.    Setting  Participants were recruited from medium security prisons in  S weden. The medication started within 2 weeks before release from prison and continued in out‐patient care with twice‐weekly visits, including once‐weekly cognitive behavioural therapy.    Participants  Fifty‐four men with a mean age of 42 years, currently incarcerated, meeting  DSM‐IV  criteria for  ADHD  and amphetamine dependence.    Measurements  Change in self‐reported  ADHD  symptoms, relapse to any drug use (amphetamine and other drugs) measured by urine toxicology, retention to treatment, craving and time to relapse.    Findings  The  MPH ‐treated group reduced their  ADHD  symptoms during the trial ( P  = 0.011) and had a significantly higher proportion of drug‐negative urines compared with the placebo group ( P  = 0.047), including more amphetamine‐negative urines ( P  = 0.019) and better retention to treatment ( P  = 0.032).    Conclusions  Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence.

addiction

Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24‐week randomized placebo‐controlled trial